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Abstract 
Review on CDK2, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
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Figure 1. Mapping of CDK2 gene on chromosome 12q13 (from GeneCards CDK2 gene) 
DNA/RNA 
Description 
One of the two different human cDNAs that can 
complement cdc28 mutations of budding yeast 
Saccharomyces cerevisiae cloned by Ninomiya et al. 
corresponds to the CDK2 gene (Ninomiya 1991). 
Elledge et al. identified CDK2 as a second functional 
p34 homolog with the help of a human cDNA 
expression library to search for suppressors of cdc28 
mutations in S. cerevisiae (Elledge 1991). CDK2 
gene is mapped to 12q13 (Demetrick 1994) (Fig. 1). 
The cloning of approximately 2.4-kilobase pair 
genomic DNA fragment from the upstream region of 
the human CDK2 gene has been described 
(Shiffman 1996). The CDK2 gene fragment was 
found to contain 5 transcription initiation sites within 
a 72-bp stretch. A 200-bp subfragment that confers 
70% of maximal basal promoter activity was shown 
to contain 2 synergistically acting Sp1  
sites (Shiffman 1996). The intron-exon boundaries 
of 7 exons in this gene were also 
identified (Shiffman 1996). There are other reports 
of CDK2 gene expressed as a 2.1 kb transcript 
encoding a polypeptide of 298 amino acids and 
encodes the human homolog of the Xenopus Eg1 
gene, sharing 89% amino acid identity (Elledge 
1991). 
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Transcription 
The presence of CDK2 mRNA was observed late in 
G1 or in early S phase, slightly before CDC2 mRNA, 
under growth stimulation in normal human fibroblast 
cells (Ninomiya 1991). CDK2 mRNA has also been 
shown to be induced by serum in several cultured 
cell types (Shiffman 1996). 
Protein 
Description 
The CDK2 protein was found to be highly 
homologous to p34CDC2 kinase (65% identical) and 
more significantly homologous to Xenopus Eg1 
kinase (89% identical), suggesting that CDK2 is the 
human homolog of Eg1 (Ninomiya 1991). CDK2 
protein has a biological activity closely related to the 
CDC28 and CDK1 (Cdc2, p34CDC2) kinases 
(Ninomiya 1991) and the protein retains nearly all of 
the amino acids highly conserved among previously 
identified p34 homologs from other species (Elledge 
1991). CDK2 is a mammalian Ser/Thr kinase that 
plays a critical role in controlling the progression 
from G1 to S phase of the cell cycle (Morgan 1997) 
and is functionally homologous to the well-studied 
cdc28a S. cerevisae protein (Zhao 2011). 
Monomeric CDK2 lacks regulatory activity 
requiring to be aroused by its positive regulators, 
cyclins E and A, or catalytic segment 
phosphorylation (Yan 2015). CDK2 activation is a 
two-step process; step one requires its association 
with the regulatory subunit cyclins A or E and step 
two involves phosphorylation of the residue Thr160 
(Marcos 2011, Morris 2002, Pavletich 1999).  
 
The crystal structure of the human CDK2 
apoenzyme and its Mg2+ATP complex have been 
determined to 2.4 Å resolution (De Bondt 1993) 
while the crystal structure of CDK2-ATP complex 
has been determined at 2.3 Å resolution (Jeffrey 
1995). Monomeric CDK2 is made of 298 amino 
acids (PDB code: 1HCL, residues 1-298), and folds 
into a typical bilobal structure, composed of  a 
smaller N-terminal lobe (residues 1-85) that consists 
of antiparallel five-strand β-sheet and a major C-
helix, together with a larger C-terminal lobe 
primarily composed of α-helix (De Bondt 1993). The 
two terminal domains are linked by a single peptide 
strand (residues 81-83) which acts as a hinge linker 
making sure that the two lobes can rotate with 
respect to each other without disruption of the 
secondary structure of this kinase (Cox 1994). Three 
binding sites have been reported in the 
monomeric CDK2 structure; the adenosine 
triphosphate (ATP) binding site (Site I) and two non-
competitive binding sites (Site II and III). An 
allosteric binding site (Site IV) is generated as a 
result of structural changes that yield a variation of 
the ATP binding site when the kinase is subjected to 
the cyclin binding process (Yan 2015). Competitive 
binding site (Site I) is the most well-known ATP 
binding site, situated deep at the junction of the N 
and C domains. It includes the pivotal catalytic 
residues with high sensitivity and linker region 
(residues 81-83), and consists of 136 consecutive 
amino acids (10-145) on the CDK2 (Knockaert 
2002). There is no association between non-
competitive binding sites (site II and III) and 
catalytic subunits (Li 2013). Site III is also known to 
accommodate short peptides that partially dissociate 
the CDK2/cyclin E complex, thus obstructing the 
enzymatic activity of CDK2 (Chen 2009). The 
allosteric binding site (site IV) also known as ANS 
fluorophore 8-anilino-1-naphthalene sulfonate) 
binding pocket is located in a region that is adjacent 
to the C-helix, away from the ATP site, 
approximately halfway of the ATP site and the C-
helix (Yan 2015). 
Localisation 
The nuclear translocation of CDK2/cyclin E and 
cyclin E binding are needed for CDK2 enzymatic 
activation and substrate targeting because the CDK2 
activating enzyme (CAK) and many of the CDK2 
targets reside in the nucleus (Blanchard 2000, 
Dietrich 1997, Keenan 2001). Intracellular 
trafficking of CDK2 is unclear though some studies 
suggest that cyclins may play a role in the 
translocation of the cyclin/CDK complex via the 
classical importin α/β pathway (Moore 1999, Moore 
2002). It is suggested that importin α binds to the 
nuclear localization signal on cyclins whereas 
importin β binds to nuclear transport machinery 
proteins as well as to cyclin-bound importin α. 
Translocation of the cyclin/CDK/importin α/β 
complex into the nucleus then occurs via an energy-
dependent process (Flores 2010). Other studies have 
demonstrated consistent concentration of 
CDK2/cyclin E in the nucleus in both Drosophila 
embryos and cultured human cells (Knoblich 
1994, Ohtsubo 1995), whereas CDK1 (Cdc2)/ 
CCNB1 (cyclin B1) is retained in the cytoplasm in 
interphase, entering the nucleus at the earliest stages 
of mitosis (Lehner and O'Farrell 1990, Pines and 
Hunter, 1994).  Other studies using egg extracts have 
shown how accumulation of CDK2/cyclin E in the 
nucleus is needed both for initiating DNA replication 
(Chevalier 1996) and preventing re-replication (Hua 
1997, Walter 1998). There are indications that 
CDK2 nuclear translocation is associated with the 
formation of molecular complexes containing active 
MAP Kinase and is dependent on MAP Kinase 
activation (Blanchard 2000). 
Function 
CDK2 activity has been indicated to be regulated by 
protein CDNK1B (p27KIP1) which inhibits CDK2 
kinase activity in G0 and early G1 phase and leads to 
cell-cycle arrest (Polyak 1994). Once combined with 
its positive regulatory subunits, CDK2 fosters the 
transition of the well-established G1/S phase 
CDK2 (cyclin dependent kinase 2)  
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boundary and drives the cell cycle through S interval 
(Shapiro 2006, Sherr 1994, Pines 1991).  
CDK2/cyclin A is a necessity for orderly S-phase 
progression (Sherr 1994), while phosphorylation of 
retinoblastoma protein ( RB1) to facilitate the G1/S 
transition is mediated by CDK2/cyclin E complex 
(Pines 1991). CDK2/cyclin E phosphorylates Rb 
leading to the release and activation of E2F 
transcription factors required to promote 
transcription of genes that encode proteins required 
for G1 to S phase progression (Dyson 1998, Nevins 
1998). CDK2 associates with both inactive and 
activated MAP Kinase and its activation is linked to 
formation of CDK2/ MAP Kinase complexes 
(Blanchard 2000). CDK2 is one of the most essential 
regulators for the transition and progression in a cell-
division cycle and plays a crucial role in regulating 
multiple events of cell division cycle including 
centrosome duplication, DNA synthesis, G1-S 
transition, and modulation of G2 progression 
(Chohan 2015, De Boer 2008, Fiset 2011, Omar 
2010). CDK2 is a requirement for robust DNA 
damage checkpoint signalling and loss of CDK2 was 
observed to cause a marked deficiency in the G2/M 
arrest which is a basic response to DNA damage in 
cells that were also nullizygous for P53 (Chung and 
Bunz, 2010). CDK2 plays a critical role in 
facilitating robust DNA damage checkpoint control 
by the ATR- CHEK1- CDC25A pathway. CDK2 
seems to promote the formation of active ATR 
complexes by ATRIP phosphorylation and by CDC6 
stabilization (Chung and Bunz, 2010). There is a 
possibility of CDK2 also controlling checkpoint 
signaling via additional mechanisms such as the 
recently described CDK2 interacting protein ( CINP) 
which facilitates robust ATR signalling (Lovejoy 
2009). In addition, loss of CDK2 was demonstrated 
to alter the regulation of several proteins that are 
known to regulate S-phase progression, but also 
control mitotic entry, including CDC25A, CHK1, 
CDC6 and ATRIP (Donzelli and Draetta, 2003, 
Borlado and Mendez 2008, Cimprich and Cortez, 
2008). Expression of CCNE1-CDK2 at physiologic 
levels of ATP results in phosphorylation of 
CDKN1B at thr187, leading to elimination of 
CDKN1B from the cell and progression of the cell 
cycle from G1 to S phase (Sheaff 1997). At low ATP 
levels, the inhibitory functions of CDKN1B are 
enhanced, thereby arresting cell proliferation (Sheaff 
1997). Apoptosis of human endothelial cells after 
growth factor deprivation is associated with rapid 
and dramatic upregulation of cyclin A-associated 
CDK2 activity (Levkau 1998).  In apoptotic cells, 
the carboxyl-termini of the CDK inhibitors 
CDKN1A and CDKN1B are truncated by specific 
cleavage aided by CASP3 and/or a CASP3-like 
caspase. After cleavage, CDKN1A loses its nuclear 
localization sequence and exits the nucleus. 
Cleavage of CDKN1A and CDKN1B resulted in a 
substantial reduction in their association with 
nuclear cyclin-CDK2 complexes, leading to a 
dramatic induction of CDK2 activity. Dominant-
negative CDK2, as well as a mutant CDKN1A 
resistant to caspase cleavage, partially suppressed 
apoptosis. CDK2 activation, through caspase-
mediated cleavage of CDK inhibitors, may be 
instrumental in the execution of apoptosis following 
caspase activation (Levkau 1998). Forkhead box O 
(FOXO) are key regulators of cell survival and 
CDK2 is known to specifically phosphorylate 
FOXO1 at ser249 in vitro and in vivo resulting into 
cytoplasmic localization and inhibition of FOXO1 
(Huang 2006).  Functional interaction between 
CDK2 and FOXO1 provides a mechanism that 
regulates apoptotic cell death after DNA strand 
breakage (Huang 2006). Proto-oncogenes such as 
MYC and RAS promote normal cell growth, fuel 
tumor development when deregulated and if over-
activated can trigger intrinsic tumor suppressor 
mechanisms leading to apoptosis and senescence 
(Hydbring and Larsson, 2010). Ras is known to 
suppress Myc-induced apoptosis while Myc was 
recently discovered to repress Ras-induced 
senescence. The ability of Myc to suppress 
senescence is dependent on its phosphorylation at 
Ser 62 by CDK2. Using CDK2 as a cofactor, Myc is 
able to directly control major genes involved in 
senescence. Selective pharmacological inhibition of 
CDK2 was observed to force Myc/Ras expressing 
cells into cellular senescence, an indication that 
CDK2 is a potential therapeutic target for treatment 
of tumors driven by Myc or Ras (Hydbring and 
Larsson, 2010). 
Implicated in 
Among all the CDKs, CDK2 is known to be an 
important kinase in tumorigenesis and proliferation 
in many cancer types including lung cancer, liver 
cancer, colon cancer and breast cancer (Opyrchal 
2014, Shi 2015, Lim 2014).  There is strong evidence 
showing that CDK2 is functionally linked with hyper 
proliferation in multiple cancer cells and is a 
potential therapeutic target for cancer therapy 
(Chohan 2015). 
Prostate cancer 
CDK2 has been found to play a pivotal role in cell 
proliferation of prostate cancer (Omar 2010). 
Breast cancer 
CDK2 is also crucial for malignant transformation of 
breast epithelial cells. Suppression of CDK2 activity 
can effectively inhibit the proliferation of human 
breast cancer cells (Ali 2009). Active CDK2 in the 
form of a cyclin D1/CDK2 fusion protein induces 
tumors that contain an invasive component that 
exhibits multiple features in common with human 
basal-like tumors and tumor-derived cell lines 
(Corsino 2008). Cyclin D1/CDK2 complexes were 
detected in human breast cancer cell lines (Sweeney 
CDK2 (cyclin dependent kinase 2)  
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1998), and the levels of these complexes correlated 
well with the degree of cyclin D1 overexpression. 
Ovarian cancer 
The role of cyclin E and its associated kinase CDK2 
in ovarian cancer has been investigated by screening 
primary, metastatic, recurrent and benign ovarian 
tumors. Using gene amplification, Cyclin E was 
shown to be amplified in 21% and CDK2 in 6.4% of 
the cases analyzed. Additionally, Cyclin E RNA was 
overexpressed in 29.5% and CDK2 in 6.5% of 
ovarian tumors tested. Cyclin E and CDK2 were 
overexpressed mostly in primary ovarian cancers 
(32% and 10%, respectively) compared to metastatic 
and recurrent diseases (Marone 1998). 
Glioblastoma 
Wang et al. identified CDK2 expression to be 
significantly elevated in glioma tumor especially in 
Glioblastoma Multiforme (GBM) and was 
functionally required for GBM cell proliferation and 
tumorigenesis (Wang 2016). CDK2 expression was 
identified to be significantly enriched in GBM 
tumors and functionally required for tumor 
proliferation both in vitro and in vivo. Additionally, 
high CDK2 expression was associated to poor 
prognosis in GBM patients. Radio resistance is a 
major factor of poor clinical prognosis and tumor 
recurrence in GBM patients. CDK2 was found to be 
one of the most up-regulated kinase encoding genes 
in GBM after radio treatment. CDK2-dependent 
radio resistance is indispensable for GBM 
tumorigenesis and recurrence after therapeutic 
treatment (Wang 2016). 
Cholangiocarcinoma 
Elevated levels of CDK2 expression have been 
observed in human cholangiocarcinoma tissues 
where apoptosis-related protein-1 dependent 
suppression of CDK2 induced cell cycle arrest and 
restrained tumor growth (Zheng 2016). 
Oral squamous cell carcinoma (SCC) 
CDK2 overexpression in oral squamous cell 
carcinoma (SCC) may elevate pRB phosphorylation 
and permit more rapid entry of the cancer cells into 
S phase. In a clinicopathological survey of oral SCC, 
incidence of CDK2 expression was high in the 
poorly differentiated lesions, and was associated 
with the mode of tumor invasion, lymph node 
involvement and survival, an indication that change 
in CDK2 expression is associated with oral cancer 
progression (Mihara 2001). CDK2 expression was 
significantly correlated with lymph node 
involvement, tumor differentiation, mode of tumor 
invasion, and shorter survival period. Increased 
expression of CDK2 is both a critical factor in oral 
cancer progression and a negative predictive marker 
of the patients' prognosis (Mihara 2001). 
Lung cancer 
CDK2 has been found to play a pivotal role in cell 
proliferation of non-small cell lung cancer (Kawana 
1998). 
Pemphigus vulgaris (PV) 
Pemphigus vulgaris (PV) is an autoimmune 
blistering disease that affects skin and mucous 
membranes. CDK2 appeared to have a role in the 
development of PV lesions (Lanza 2008). Exposing 
of synchronized human keratinocytes to PV serum 
increased the proportion of cells in S phase, caused 
cell rounding and cell-cell detachment, elevated 
CDK2 expression in a dose-dependent manner, and 
altered the expression of over 500 genes especially 
those that are involved in cell communication and 
cell- cell junction formation. Small interfering RNA 
against CDK2 reversed PV serum-induced CDK2 
overexpression and reduced cell-cell detachment. By 
utilizing a neonatal mouse model in which PV 
lesions were induced by a single intraperitoneal 
injection of whole serum obtained from a PV 
patient, it was shown that pre-treatment of mice with 
a pharmacologic CDK2 inhibitor prevented skin 
lesion development and PV serum-induced changes 
in gene expression. Histochemical analysis of PV 
patient skin revealed CDK2 overexpression around 
the site of the acantholytic cleft and along suprabasal 
layers in perilesional sites. It was finally concluded 
that activation of CDK2-mediated signaling is an 
essential event in the development of PV lesions 
(Lanza 2008). 
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